Gleevec
Novartis’ Scemblix Demonstrates Superior Efficacy and Safety in Newly Diagnosed Leukemia Patients ###
Novartis, Scemblix, Leukemia, Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKIs), Gleevec, American Society of Clinical Oncology (ASCO)